Find information on thousands of medical conditions and prescription drugs.

Fentanyl

Fentanyl is an opioid analgesic, first synthesized in Belgium in the late 1950s, with an analgesic potency of about 80 times that of morphine. It was introduced into medical practice in the 1960s as an intravenous anesthetic under the trade name of Sublimaze. Fentanyl has an LD50 of 3.1 milligrams per kilogram in rats. The LD50 in humans is not known. Fentanyl is a Schedule II drug. more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Analogues

The pharmaceutical industry has developed several analogues of fentanyl:

  • Alfentanil (Alfenta), an ultra-short acting (5–10 minutes) analgesic,
  • Sufentanil (Sufenta), a potent analgesic (15 to 10 times more potent than fentanyl) for use in heart surgery.
  • Remifentanil, currently the shortest acting opioid, has the benefit of rapid offset, even after prolonged infusions.
  • Carfentanil (Wildnil) is an analogue of fentanyl with an analgesic potency 10,000 times that of morphine and is used in veterinary practice to immobilize certain large animals.

Therapeutic use

Today, fentanyls are extensively used for anesthesia and analgesia. Duragesic, by Janssen Pharmaceutica, is a fentanyl transdermal patch used in chronic pain management. In the past few years, this compound has gone generic and is available for lower cost. Duragesic is manufactured in five patch sizes. They are 12.5 mcg/hr, 25 µg/h, 50 µg/h, 75 µg/h, and 100 µg/h. Dosage is based on the size of the patch, since the transdermal absorption rate is generally constant at skin temperature.

Actiq, by Cephalon, is a recently-developed solid formulation of fentanyl citrate on a stick that dissolves slowly in the mouth for transmucosal absorption. Actiq is intended for opiate-tolerant individuals and is effective in treating breakthrough cancer pain. It is also useful for breakthrough pain for those suffering bone injuries, severe back pain, neuropathy, arthritis, and some other examples of chronic nonmalignant pain. The unit is a berry-flavored lozenge on a stick which is swabbed on the mucosal surfaces inside the mouth - under and on the tongue and gums—to release the fentanyl quickly into the system. It is most effective when the lozenge is consumed in 15 minutes. The drug is practically ineffective if swallowed, absorption from the alimentary tract being negligible. Actiq is available in 6 dosages, from 200 µg to 1,600 µg (There are no 1,000 µg or 1,400 µg doses)in 200 µg increments.

Fentanyl is frequently given intrathecally as part of spinal anesthesia or epidurally for epidural anesthesia and analgesia.

Illicit use

Illicit use of pharmaceutical fentanyls first appeared in the mid-1970s in the medical community and continues to be a problem in the United States. United States authorities classify fentanyl as a narcotic. To date, over 12 different analogues of fentanyl have been produced clandestinely and identified in the U.S. drug traffic. The biological effects of the fentanyls are indistinguishable from those of heroin, with the exception that the fentanyls may be hundreds of times more potent. Also, fentanyl has a shorter duration than heroin does. Fentanyls are most commonly used by intravenous administration, but like heroin, they may also be smoked or snorted. One common street name for fentanyl is china white. This is not always accurate, as it was originally given to alpha-methyl-fentanyl, although in recent years this terminology has faded somewhat. AMF has longer metabolism than fentanyl because the methyl group retards metabolism.

Read more at Wikipedia.org


[List your site here Free!]


Transdermal Fentanyl vs. Sustained-Release Morphine - for the treatment of persistent pain
From American Family Physician, 1/15/02 by Anne D. Walling

Around 20 percent of primary care patients report having persistent pain. Although pain is one of the most common reasons for consultation with a physician, the condition is difficult to treat, and patients frequently are dissatisfied with conventional medical care. Legal regulations, prejudice, and continuing ignorance limit use of the most effective agents in cancer pain management--opioids. Studies in patients with cancer have found better pain control and improved quality of life with transdermal fentanyl compared to sustained-release oral morphine. Allan and colleagues compared transdermal fentanyl to sustained-release oral morphine in patients with noncancer chronic pain in a large, multicenter, two-way, crossover trial.

Patients requiring continuous potent opioids to treat chronic noncancer pain were recruited from 35 specialist pain clinics in seven countries. Standardized assessments of pain and quality of life were completed after each treatment and at the end of the study as part of the comprehensive assessment. The 256 patients were randomly assigned to initial treatment with sustained-release oral morphine or transdermal fentanyl in individualized doses calculated from the requirement for opioid immediately before the patient entered the trial. After four weeks, the treatments were reversed for a second treatment period of four weeks.

Data were available for 212 patients who completed the study. Transdermal fentanyl was preferred, or very much preferred, by 138 patients (65 percent) compared with 59 patients (28 percent) who preferred oral morphine. Average pain intensity scores were significantly lower during fentanyl treatment. A significantly higher proportion of patients reported good or very good pain control during fentanyl treatment (35 percent compared with 23 percent). The type of pain did not influence the results.

Patients also reported higher quality of life scores during fentanyl therapy in the overall scores, and in categories such as bodily pain, vitality, social functioning, and mental health. The incidence of adverse effects was similar in both groups, with more than 70 percent of patients reporting adverse effects. Serious adverse effects were less common during fentanyl therapy; nausea was more common and constipation less common during fentanyl therapy than during morphine treatment. More patients withdrew during fentanyl therapy than during morphine therapy. The percentage withdrawing because of adverse effects (11 percent) during fentanyl therapy was double that during morphine therapy.

The authors conclude that transdermal fentanyl therapy provides superior pain relief and is associated with enhanced quality of life compared to oral morphine in patients with chronic noncancer pain.

COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Fentanyl
Home Contact Resources Exchange Links ebay